EDAP Appoints Senior Marketing Director; Company to Increase Marketing Efforts to Patients and Physicians Across Europe
23 September 2005 - 4:59AM
PR Newswire (US)
LYON, France, Sept. 22 /PRNewswire-FirstCall/ -- EDAP TMS S.A.
(NASDAQ:EDAP), the world leader in High Intensity Focused
Ultrasound treatment of localized prostate cancer, is pleased to
announce the appointment of Fabrice Romano to the position of
Senior Marketing Director. In this role, Romano will direct market
education programs aimed at doctors and patients in new and
existing markets for EDAP's Ablatherm-HIFU product. He will also
direct documentation of Ablatherm-HIFU clinical data for
distribution in marketing programs, support the sales force in
building markets and assist in accelerating reimbursement process
in key European countries. Romano was previously the European
marketing manager for Sofradim, a leading French company in
manufacturing surgical implants used in general and
uro-gynecological surgery, where he oversaw the distribution
network and developed marketing efforts directed at key opinion
leaders. Romano has also served as marketing and sales manager for
Biomatech, a private lab for the development and testing of medical
devices and Domilens, now Bausch & Lomb Surgical, as sales
manager for France. He also has direct experience in developing
marketing, communication and training multimedia tools for pharmacy
and medical device manufacturers, including Pfizer, Johnson &
Johnson, Novartis, Wyeth and Medtronic, while directing his own
company, Multi Active. He is a 1987 graduate of the French
Veterinary Schools specializing in ophthalmology and microsurgery.
He has been working since 1989 in the human healthcare field.
Romano is fluent in French, Italian and English. "Joining EDAP is
an amazing opportunity to be involved in a business challenge which
consists of convincing the worldwide urology community that our
HIFU technology is certainly the best alternative for localized
prostate cancer treatment, combining excellent results and a very
low rate of side effects," Romano said. "EDAP has already
accumulated a significant body of clinical evidence and support of
key urology opinion leaders in many countries. There is clearly
strong momentum moving Ablatherm forward into the mainstream of
prostate cancer treatment." Hugues de Bantel, EDAP's Chief
Executive Officer, commented, "EDAP has made significant progress
in developing treatment centers across Europe over the past several
years. Adding a Director of Marketing allows us to more
aggressively address the marketplace and build knowledge of the
unique benefits Ablatherm-HIFU offers as well as grow interest in
the patient population by informing them of the lower side effects
and quick recovery available to them in treating prostate cancer.
Fabrice has a unique background in growing the markets for medical
devices by communicating with both patients and doctors, which will
serve EDAP well as we continue to establish more centers in
countries currently using Ablatherm and develop new markets
worldwide." About EDAP TMS S.A. EDAP TMS S.A. develops and markets
Ablatherm, the most advanced and clinically proven choice for High
Intensity Focused Ultrasound (HIFU) treatment of localized prostate
cancer. HIFU treatment is shown to be a minimally invasive and
effective treatment option with a low occurrence of side effects.
The company is also developing this technology for the treatment of
certain other types of tumors. EDAP TMS S.A. also produces and
commercializes medical equipment for treatment of urinary tract
stones using Extra-corporeal Shockwave Lithotripsy (ESWL). For more
information on the Company, contact the Investor Relations Dept by
phone at +33 (0)4 78 26 40 46 or see the Company's Web site at:
http://www.edap-tms.com/ . This press release contains, in addition
to historical information, forward-looking statements that involve
risks and uncertainties. These include statements regarding the
Company's growth and expansion plans. Such statements are based on
management's current expectations and are subject to a number of
uncertainties and risks that could cause actual results to differ
materially from those described in the forward-looking statements.
Factors that may cause such a difference include, but are not
limited to, those described in the Company's filings with the
Securities and Exchange Commission. CONTACT: EDAP TMS S.A. Hugues
de Bantel - Philippe Chauveau Blandine Confort +33 4 78 26 40 46
Halliburton Investor Relations Matt Kreps - Geralyn DeBusk 972 458
8000 DATASOURCE: EDAP TMS S.A. CONTACT: Hugues de Bantel, or
Philippe Chauveau, or Blandine Confort, all of EDAP TMS S.A.,
+33-4-78-26-40-46; or Matt Kreps or Geralyn DeBusk, both of
Halliburton Investor Relations, +1-972-458-8000, for EDAP TMS S.A.
Web site: http://www.edap-tms.com/
Copyright
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jun 2024 to Jul 2024
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jul 2023 to Jul 2024